HUTCHMED (China) (HCM) H2 2024 earnings summary

Executive summary

• Achieved net profit in 2024 ahead of schedule, driven by global commercial success of FRUZAQLAⓇ and robust China performance of ELUNATEⓇ and SULANDAⓇ, with $290.6 million in FRUZAQLAⓇ sales.

• 2024 marked by rapid international expansion, new product launches, and multiple regulatory approvals in China and abroad.

• Strong commercial performance across the oncology portfolio, with in-market sales exceeding $500 million, more than doubling 2023 sales.

• Strong cash position ($836 million) and strategic focus on self-sustaining growth, with 6-7 products in China and 2-3 globally in the medium term.

• Significant pipeline progress, including approvals and positive trial results for savolitinib, fruquintinib, and new ATTC platform advancements.

Financial highlights

• 2024 total revenue $630.2 million, down from $838.0 million in 2023 due to lower upfront/milestone payments, but oncology product revenue grew to $271 million (+65% year-over-year).

• Net income reported at $37.7 million for the year.

• Oncology in-market sales reached $501 million (+134% year-over-year), led by FRUZAQLAⓇ ($291 million, +1,825%) and ELUNATEⓇ ($115 million, +7%).

• R&D expenses reduced to $212 million (from $302 million), and selling/admin expenses cut by $113 million, reflecting portfolio prioritization and cost control.

• Cash, cash equivalents, and short-term investments at $836 million as of Dec 31, 2024.

Outlook and guidance

• 2025 oncology revenue guidance set at $350–450 million, reflecting non-recurring 2024 income from Takeda and expectations for continued strong sales growth from FRUZAQLAⓇ and new indications in China.

• Near-term catalysts include multiple regulatory filings and approvals (e.g., SAVANNAH, SACHI, Tazemetostat, Sovleplenib) and further global expansion.

• Plans to leverage strong cash position for product acquisitions or M&A, focusing on late-stage or synergistic oncology/immunology assets.

• Continued profitability and self-sustaining operations anticipated.

• Mid-term strategy leverages strong cash to acquire new products for China; long-term focus on advancing ATTC platform and novel candidates.